Moat Ross — SEC Form 4 filings
SEC reporting owner CIK 1857177. 16 Form 4 filings on record with FilingPulse; latest filed 2026-09-03.
Transaction summary — filings shown
Covers all 16 filings on record, filed 2024-04-03 to 2026-09-03. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 11 legs across 8 filings — 219,343 shares, $5,828,097 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 102.
- Largest priced transaction: sale of 67,346 shares @ $26.10 ($1,757,731) in Kiniksa Pharmaceuticals International, plc, filed 2024-09-04.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Kiniksa Pharmaceuticals International, plc (KNSA) | CHIEF OPERATING OFFICER | 16 | — | 11 legs · 219,343 sh · $5,828,097 | 102 |
Form 4 filings — Moat Ross
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-03 | 4 | Kiniksa Pharmaceuticals International, plc (KNSA) | Option exercise (M): 2,477 · Option exercise (M): 1,611 · Option exercise (M): 1,740 · Option exercise (M): 2,457 · Tax withholding (F): 4,007 @ $79.28 · Grant/award (A): 9,250 (derivative) @ $0 · +5 more | EDGAR |
| 2026-04-13 | 4 | Kiniksa Pharmaceuticals International, plc (KNSA) | Sale (S): 1,703 @ $46.69 | EDGAR |
| 2026-04-08 | 4 | Kiniksa Pharmaceuticals International, plc (KNSA) | Sale (S): 2,367 @ $48.58 · Option exercise (M): 2,477 · Tax withholding (F): 774 @ $48.94 · Option exercise (M): 2,477 (derivative) @ $0 | EDGAR |
| 2026-04-03 | 4 | Kiniksa Pharmaceuticals International, plc (KNSA) | Grant/award (A): 879 @ $24.16 · Option exercise (M): 5,808 · Tax withholding (F): 1,706 @ $48.13 · Grant/award (A): 36,950 (derivative) @ $0 · Grant/award (A): 9,250 (derivative) @ $0 · Grant/award (A): 18,500 (derivative) @ $0 · +3 more | EDGAR |
| 2025-09-08 | 4 | Kiniksa Pharmaceuticals International, plc (KNSA) | Sale (S): 3,523 @ $35.31 | EDGAR |
| 2025-09-03 | 4 | Kiniksa Pharmaceuticals International, plc (KNSA) | Option exercise (M): 1,741 · Option exercise (M): 1,611 · Option exercise (M): 2,477 · Tax withholding (F): 2,819 @ $33.49 · Option exercise (M): 994 · Tax withholding (F): 481 @ $34.28 · +6 more | EDGAR |
| 2025-06-05 | 4 | Kiniksa Pharmaceuticals International, plc (KNSA) | Option exercise (M): 27,594 @ $13.35 · Sale (S): 27,594 @ $29.02 · Option exercise (M): 27,594 (derivative) @ $0 | EDGAR |
| 2025-05-05 | 4 | Kiniksa Pharmaceuticals International, plc (KNSA) | Option exercise (M): 3,850 @ $17.76 · Sale (S): 3,850 @ $28 · Option exercise (M): 6,272 @ $17.76 · Sale (S): 6,272 @ $28 · Grant/award (A): 4,976 (derivative) @ $0 · Grant/award (A): 5,225 (derivative) @ $0 · +4 more | EDGAR |
| 2025-05-01 | 4 | Kiniksa Pharmaceuticals International, plc (KNSA) | Option exercise (M): 15,000 @ $15.52 · Option exercise (M): 20,000 @ $15.50 · Option exercise (M): 6,296 @ $12.97 · Option exercise (M): 7,432 @ $11.97 · Option exercise (M): 15,307 @ $10.76 · Sale (S): 64,035 @ $25.21 · +12 more | EDGAR |
| 2025-04-23 | 4 | Kiniksa Pharmaceuticals International, plc (KNSA) | Sale (S): 18,259 @ $20.29 | EDGAR |
| 2025-04-09 | 4 | Kiniksa Pharmaceuticals International, plc (KNSA) | Option exercise (M): 2,477 · Tax withholding (F): 727 @ $20.28 · Option exercise (M): 2,477 (derivative) @ $0 | EDGAR |
| 2025-04-03 | 4 | Kiniksa Pharmaceuticals International, plc (KNSA) | Option exercise (M): 1,611 · Option exercise (M): 1,741 · Tax withholding (F): 473 @ $21.77 · Tax withholding (F): 511 @ $21.77 · Grant/award (A): 39,364 (derivative) @ $0 · Grant/award (A): 9,828 (derivative) @ $0 · +3 more | EDGAR |
| 2025-03-19 | 4 | Kiniksa Pharmaceuticals International, plc (KNSA) | Grant/award (A): 1,118 @ $16 · Option exercise (M): 994 · Tax withholding (F): 292 @ $22.61 · Option exercise (M): 994 (derivative) @ $0 | EDGAR |
| 2024-09-04 | 4 | Kiniksa Pharmaceuticals International, plc (KNSA) | Grant/award (A): 211 @ $15.65 · Option exercise (M): 4,089 · Tax withholding (F): 1,393 @ $26.74 · Option exercise (M): 994 · Tax withholding (F): 345 @ $26.74 · Option exercise (M): 14,000 @ $8.83 · +12 more | EDGAR |
| 2024-04-08 | 4 | Kiniksa Pharmaceuticals, Ltd. (KNSA) | Option exercise (M): 2,477 · Tax withholding (F): 1,353 @ $17.90 · Grant/award (A): 36,100 (derivative) @ $0 · Grant/award (A): 5,569 (derivative) @ $0 · Grant/award (A): 6,962 (derivative) @ $0 · Option exercise (M): 2,477 (derivative) @ $0 | EDGAR |
| 2024-04-03 | 4 | Kiniksa Pharmaceuticals, Ltd. (KNSA) | Option exercise (M): 1,612 · Tax withholding (F): 880 @ $19.70 · Option exercise (M): 1,612 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1857177 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →